Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
LONDON, February 26, 2013 /PRNewswire/ --
According to the World Health Organization and CDC, more than 500 million people worldwide and approximately one-third of American adults (more than 78 million people) are obese. In addition to obesity, high cholesterol, blood pressure and triglycerides are significant risk factors for cardiovascular disease. Biotechnology companies like Vivus Inc. (NASDAQ: VVUS) and Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) would be instrumental in providing cure and medicines for growing number of diseases. StockCall has posted free technical research on VIVUS Inc. and Achillion Pharmaceutical which can be downloaded upon sign up at
Vivus Inc. announces publication of an encouraging study on Qsymia
Vivus Inc. is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets. The company announced the publication of a study concluding that weight loss resulting from treatment with Qsymia™(phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost 10% or more of their starting weight. Sign up and read the complimentary report on VIVUS Inc. at
"This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors," said Suzanne Oparil, M.D., Director of the Vascular Biology and Hypertension Program, University of Alabama at Birmingham, and an investigator in the study.
At Vuvus, Qsymia is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Achillion Pharmaceuticals announces pricing of public offering of common stock
Achillion Pharmaceuticals Inc. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious diseases and is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. The company announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $118.5 million. The free report on Achillion Pharmaceuticals Inc. can be downloaded by signing up now at
The offering is expected to close on February 27, 2013, subject to customary closing conditions. Citigroup and Leerink Swann LLC are acting as joint book-running managers, and JMP Securities LLC, Piper Jaffray & Co. and Wells Fargo Securities, LLC are acting as co-managers for the offering.
Achillion has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. The expected net proceeds to Achillion referenced above do not include any net proceeds that Achillion would receive if the underwriters exercise such option.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
©2012 PR Newswire. All Rights Reserved.